中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

514 records (took 0.031 seconds)

    Non-invasive imaging for determination of global tissue characteristics
    83.
    发明授权
    Non-invasive imaging for determination of global tissue characteristics 有权
    用于确定全局组织特征的非侵入性成像

    公开(公告)号：US08874192B2

    公开(公告)日：2014-10-28

    申请号：US13961581

    申请日：2013-08-07

    Applicant: Wake Forest University Health Sciences

    Inventor： William Gregory Hundley ,  Craig A. Hamilton ,  Kimberly Lane ,  Tim Morgan ,  Frank Torti

    IPC: A61B5/05 ,  G01R33/56 ,  G06T7/00 ,  A61B6/00 ,  G06T7/40 ,  A61B5/055 ,  A61B5/00 ,  A61B6/03 ,  G01R33/28

    CPC classification number: A61B5/0033 ,  A61B5/055 ,  A61B5/42 ,  A61B5/4519 ,  A61B6/032 ,  A61B6/503 ,  A61B6/504 ,  A61B6/506 ,  G01R33/281 ,  G01R33/56 ,  G06T7/0014 ,  G06T7/41 ,  G06T2200/24 ,  G06T2207/10088 ,  G06T2207/30048

    Abstract: Evaluating tissue characteristics including identification of injured tissue or alteration of the ratios of native tissue components such as shifting the amounts of normal myocytes and fibrotic tissue in the heart, identifying increases in the amount of extracellular components or fluid (like edema or extracellular matrix proteins), or detecting infiltration of tumor cells or mediators of inflammation into the tissue of interest in a patient, such as a human being, is provided by obtaining a first image of tissue including a region of interest from a first acquisition, and obtaining a second image of the tissue including the region of interest during a second, subsequent acquisition. The subsequent acquisition may be obtained after a period of time to determine if injury has occurred during that period of time. Such a comparison may include comparison of mean, average characteristics, histogram shape, such as skew and kurtosis, or distribution of intensities within the histogram.

    Abstract translation: 评估组织特征，包括识别损伤的组织或改变天然组织成分的比例，例如改变心脏中正常心肌细胞和纤维组织的量，鉴定细胞外组分或液体量的增加（如水肿或细胞外基质蛋白） ，或者通过从第一次获取获得包括感兴趣区域的组织的第一图像，或通过从第一次获取获得包括感兴趣区域的组织的第一图像来检测肿瘤细胞或炎症介质的浸润到患者（例如人）中的感兴趣组织，并获得第二图像 包括在第二次后续采集期间的感兴趣区域的组织。 随后的收购可能会在一段时间后获得，以确定在此期间是否发生损伤。 这种比较可以包括平均值，平均特征，直方图形状（例如偏斜和峰度）或直方图内的强度分布的比较。

    Method for detecting compounds containing sulfenic acid using a 1,3-cyclohexanedione-based probe
    84.
    发明授权
    Method for detecting compounds containing sulfenic acid using a 1,3-cyclohexanedione-based probe 有权
    使用1,3-环己二酮基探针检测含有亚磺酸的化合物的方法

    公开(公告)号：US08841132B2

    公开(公告)日：2014-09-23

    申请号：US13920989

    申请日：2013-06-18

    Applicant: Wake Forest University Health Sciences

    Inventor： Leslie B. Poole ,  S. Bruce King ,  Jacquelyn S. Fetrow

    IPC: G01N33/68 ,  G01N33/52 ,  G01N21/64 ,  G01N33/574

    CPC classification number: G01N33/68 ,  G01N21/6428 ,  G01N33/574 ,  G01N33/6815 ,  Y10T436/156666 ,  Y10T436/182 ,  Y10T436/24

    Abstract: The present invention provides compounds of Formula I: wherein: R1 is a label (e.g., a detectable group and an anti-tumor agent); L is present or absent and when present is a linking group; and x represents an integer from 1 to 10; or a pharmaceutically acceptable salt thereof. The compounds are useful for, among other things, identifying cysteine sulfenic acids in proteins and monitoring oxidative damage in proteins and cells. Adduct formation can be detected using analytical methods such as electrospray ionization mass spectrometry and fluorescence.

    Abstract translation: 本发明提供式I化合物：其中：R1是标记（例如可检测组和抗肿瘤剂）; L存在或不存在，并且当存在时是连接基团; x表示1〜10的整数， 或其药学上可接受的盐。 该化合物尤其可用于鉴定蛋白质中的半胱氨酸亚磺酸并监测蛋白质和细胞中的氧化损伤。 可以使用电喷雾离子化质谱和荧光等分析方法检测加合物形成。

    METHODS OF TREATING CANCEROUS TISSUE
    86.
    发明申请
    METHODS OF TREATING CANCEROUS TISSUE 审中-公开
    治疗硬组织的方法

    公开(公告)号：US20130304050A1

    公开(公告)日：2013-11-14

    申请号：US13838814

    申请日：2013-03-15

    Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES

    Inventor： Suzy V. Torti ,  Frank M. Torti ,  Andrew Ryan Burke ,  Ravi Nandan-Singh

    IPC: A61B18/18

    CPC classification number: A61B18/18 ,  A61N5/02 ,  A61N5/062 ,  A61N2005/0659

    Abstract: In one aspect, methods of treating cancerous tissue are described herein. In some embodiments, a method of treating cancerous tissue comprises inducing necrotic cell death in cancer stem cells in vivo during hyperthermic treatment of the tissue, wherein inducing necrotic cell death comprises positioning nanoparticles adjacent to the cancer stem cells and irradiating the nanoparticles with electromagnetic radiation resulting in membrane damage to the cancer stem cells.

    Abstract translation: 在一个方面，本文描述了治疗癌组织的方法。 在一些实施方案中，治疗癌组织的方法包括在组织的高热处理期间在体内诱导癌干细胞中的坏死细胞死亡，其中诱导坏死性细胞死亡包括将纳米颗粒定位在癌干细胞附近并用电磁辐射照射纳米颗粒， 在膜损伤癌症干细胞。

    MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS
    89.
    发明申请
    MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS 审中-公开
    多层次特异性靶向癌细胞

    公开(公告)号：US20130164257A1

    公开(公告)日：2013-06-27

    申请号：US13718166

    申请日：2012-12-18

    Applicant: Wake Forest University Health Sciences

    Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

    IPC: C07K19/00

    CPC classification number: C07K14/5437 ,  A61K38/00 ,  A61K47/642 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K14/34 ,  C07K19/00 ,  C07K2319/01 ,  C07K2319/09 ,  C07K2319/74 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/532 ,  G01N33/6869 ,  G01N2333/025 ,  G01N2333/195 ,  G01N2333/5437

    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

    Abstract translation: 化合物，其组合包含：细胞表面结合配体或内在因子，例如IL-13Rα2结合配体; 至少一个效应分子（例如，一个，两个，三个或更多个效应分子）; 任选但优选地，共价偶联在所述结合配体和所述至少一个效应分子之间的细胞质定位元件; 以及在所述结合配体和所述至少一个效应分子之间共价偶联的亚细胞区室定位信号元件（优选与所述结合配体和所述亚细胞定位信号元件之间的所述细胞质定位元件）。 还描述了使用这些化合物的方法和含有该化合物的制剂。

Patent Agency Ranking